Basic Information
| LncRNA/CircRNA Name | PVT1 |
| Synonyms | NA |
| Region | GRCh38_8:127794533-128101253 |
| Ensemble | ENSG00000249859 |
| Refseq | NR_003367 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Luciferase reporter assay, in vitro knockdown, RNAi |
| Sample | hepatocellular carcinoma tissues, cell lines (Bel-7402 and QGY-7703) |
| Expression Pattern | up-regulated |
| Function Description | We found that PVT1 was markedly overexpressed in HCC tissue than in normal liver tissues based on both RT-qPCR and data from TCGA, and the overexpression of PVT1 was closely related to the gender and race of the patient as well as to higher HCC tumor grades. Additionally, the upregulation of PVT1 could promote HCC cell proliferation in vitro and vivo. Furthermore, a negative correlation trend was found between miR-424-5p and PVT1 based on RT-qPCR, whereas a positive correlation trend was found between PVT1 and INCENP based on data from TCGA. Also, INCENP small interfering RNA (siRNA) could significantly inhibit cell proliferation and viability. |
| Pubmed ID | 29975928 |
| Year | 2018 |
| Title | A Preliminary Investigation of PVT1 on the Effect and Mechanisms of Hepatocellular Carcinoma: Evidence From Clinical Data, a Meta-Analysis of 840 Cases, and In Vivo Validation |
External Links
| Links for PVT1 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |